Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
New offering to debut at the 32nd ESGCT Congress, October 7–10, 2025, in Seville, Spain
Alembic receives EIR from USFDA for facility at Panelav
Hemant Surgical Industries receives order
The Ma’anshan site approval covers pastilles, oral liquids, and powders
Combination creates a leading, next generation claims operating system for payers, with end-to-end AI capabilities for claims, payments, care & utilization management, payment integrity, and member engagement, serving 115+ health plans
It will focus on interface between API and formulation manufacturing, reducing carbon footprint in formulation production, creating intellectual property, training next-generation scientists, and setting new industry benchmarks
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
Subscribe To Our Newsletter & Stay Updated
